189 related articles for article (PubMed ID: 16029707)
1. Eruptive epidermoid cysts resulting from treatment with imiquimod.
Marty CL; Randle HW; Walsh JS
Dermatol Surg; 2005 Jul; 31(7 Pt 1):780-2; discussion 782-3. PubMed ID: 16029707
[TBL] [Abstract][Full Text] [Related]
2. [Eruptive epidermoid cysts during topical imiquimod treatment].
Dillies AS; Gras-Champel V; Fraitag-Spinner S; Al Saïf F; Carmi E
Ann Dermatol Venereol; 2017 Mar; 144(3):212-215. PubMed ID: 27765414
[TBL] [Abstract][Full Text] [Related]
3. [Eruptive epidermoid cysts after imiquimod treatment of recurrent basal cell carcinoma : A case report].
Woltsche N; El-Shabrawi-Caelen L; Deinlein T; Kupsa R; Gschwandtner M; Hofmann-Wellenhof R; Zalaudek I
Hautarzt; 2019 May; 70(5):363-366. PubMed ID: 30694354
[TBL] [Abstract][Full Text] [Related]
4. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage.
Neville JA; Williford PM; Jorizzo JL
J Drugs Dermatol; 2007 Sep; 6(9):910-4. PubMed ID: 17941362
[TBL] [Abstract][Full Text] [Related]
5. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
Vidal D; Matías-Guiu X; Alomar A
Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
[TBL] [Abstract][Full Text] [Related]
6. Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series.
Huber A; Huber JD; Skinner RB; Kuwahara RT; Haque R; Amonette RA
Dermatol Surg; 2004 Mar; 30(3):429-30. PubMed ID: 15008876
[TBL] [Abstract][Full Text] [Related]
7. Imiquimod and pulmonary embolism: a case report.
Leroy B; Richez A; Wolf F; Descotes J; Vial T
Therapie; 2014; 69(2):180-1. PubMed ID: 24926639
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens.
Shumack S; Robinson J; Kossard S; Golitz L; Greenway H; Schroeter A; Andres K; Amies M; Owens M
Arch Dermatol; 2002 Sep; 138(9):1165-71. PubMed ID: 12224977
[TBL] [Abstract][Full Text] [Related]
9. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion.
Sterry W; Ruzicka T; Herrera E; Takwale A; Bichel J; Andres K; Ding L; Thissen MR
Br J Dermatol; 2002 Dec; 147(6):1227-36. PubMed ID: 12452875
[TBL] [Abstract][Full Text] [Related]
10. Multiple and clustered eruptive epidermoid cysts following treatment with topical imiquimod.
Nasca MR; De Pasquale R; Micali G
Dermatology; 2007; 215(4):352-3. PubMed ID: 17911995
[TBL] [Abstract][Full Text] [Related]
11. The ophthalmic side-effects of imiquimod therapy in the management of periocular skin lesions.
Cannon PS; O'Donnell B; Huilgol SC; Selva D
Br J Ophthalmol; 2011 Dec; 95(12):1682-5. PubMed ID: 20702431
[TBL] [Abstract][Full Text] [Related]
12. Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions.
Wagstaff AJ; Perry CM
Drugs; 2007; 67(15):2187-210. PubMed ID: 17927284
[TBL] [Abstract][Full Text] [Related]
13. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
[TBL] [Abstract][Full Text] [Related]
14. Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma.
Gowda S; Tillman DK; Fitzpatrick JE; Gaspari AA; Goldenberg G
J Cutan Pathol; 2009 Aug; 36(8):878-81. PubMed ID: 19586497
[TBL] [Abstract][Full Text] [Related]
15. Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study.
Vun Y; Siller G
Australas J Dermatol; 2006 Aug; 47(3):169-71. PubMed ID: 16866996
[TBL] [Abstract][Full Text] [Related]
16. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience.
Tillman DK; Carroll MT
Cutis; 2007 Mar; 79(3):241-8. PubMed ID: 17674590
[TBL] [Abstract][Full Text] [Related]
17. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial.
Bath-Hextall F; Ozolins M; Armstrong SJ; Colver GB; Perkins W; Miller PS; Williams HC;
Lancet Oncol; 2014 Jan; 15(1):96-105. PubMed ID: 24332516
[TBL] [Abstract][Full Text] [Related]
18. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe.
Gollnick H; Barona CG; Frank RG; Ruzicka T; Megahed M; Tebbs V; Owens M; Stampone P
Eur J Dermatol; 2005; 15(5):374-81. PubMed ID: 16172048
[TBL] [Abstract][Full Text] [Related]
19. Topical Imiquimod as a Treatment Option for Nodular Basal Cell Carcinoma: A Systematic Review.
Huang CM; Kirchhof MG
J Cutan Med Surg; 2020; 24(5):495-503. PubMed ID: 32527151
[TBL] [Abstract][Full Text] [Related]
20. Topical treatment of basal cell carcinoma with the immune response modifier imiquimod.
Papakostas D; Stockfleth E
Future Oncol; 2015 Nov; 11(22):2985-90. PubMed ID: 26450707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
